Want to see SE:XBRANE full AI Analyst Report?
Xbrane Biopharma AB (XBRANE) AI Stock Analysis
Xbrane Biopharma AB
(Nasdaq OMX AB:XBRANE)
The score is primarily constrained by severe losses and ongoing cash burn, while low leverage and generally constructive medium- to long-term technical positioning provide partial support. The negative P/E and lack of dividend yield further limit the score.
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 291.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 89.17K
- Price to Earnings (P/E)
- -7.2
- Beta (1Y)
- 0.60
- Revenue Growth
- -38.80%
- EPS Growth
- -120.18%
- Country
- Sweden
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Xbrane Biopharma AB Business Overview & Revenue Model
Company Description
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibi...
How the Company Makes Money
Xbrane makes money primarily through biosimilar-related commercialization and partnering economics. Key revenue streams can include: (1) Net sales/royalties and related commercial income from biosimilar products where Xbrane has a commercial interest...
Xbrane Biopharma AB Financial Statement Overview
Summary
Revenue grew 53.6% and leverage is low, but severe operating and net losses, negative margins, and negative operating and free cash flow materially weaken financial performance.
Income Statement
25NegativeBalance Sheet
75PositiveCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 127.95M | 152.35M | 198.70M | 238.73M | 57.62M | 11.53M |
| Gross Profit | 8.85M | 74.94M | 180.47M | 35.39M | 41.04M | -684.00K |
| EBITDA | -46.96M | -16.50M | -181.97M | -282.03M | -149.34M | -168.37M |
| Net Income | -62.68M | 127.24M | -266.22M | -388.17M | -172.23M | -191.01M |
Balance Sheet | ||||||
| Total Assets | 618.36M | 671.62M | 842.43M | 653.51M | 690.51M | 688.43M |
| Cash, Cash Equivalents and Short-Term Investments | 37.41M | 86.59M | 124.33M | 65.40M | 193.99M | 295.18M |
| Total Debt | 63.93M | 58.31M | 191.72M | 231.48M | 38.22M | 44.38M |
| Total Liabilities | 91.21M | 110.97M | 633.89M | 482.17M | 265.63M | 256.69M |
| Stockholders Equity | 527.15M | 560.65M | 208.54M | 171.34M | 424.89M | 431.74M |
Cash Flow | ||||||
| Free Cash Flow | -87.83M | -390.33M | -185.97M | -423.45M | -254.04M | -296.96M |
| Operating Cash Flow | -76.80M | -250.69M | -133.73M | -406.68M | -193.92M | -219.61M |
| Investing Cash Flow | -34.38M | -37.14M | -52.25M | -16.77M | -60.13M | -77.35M |
| Financing Cash Flow | 56.47M | 255.60M | 243.62M | 298.70M | 148.86M | 349.37M |
Xbrane Biopharma AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 13.00 is below the 20-day moving average (MA) of 13.14, above the 50-day MA of 11.36, and above the 200-day MA of 9.92, indicating a bullish trend. The MACD of 0.84 indicates Negative momentum. The RSI at 55.31 is Neutral, neither overbought nor oversold. The STOCH value of 35.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.
Xbrane Biopharma AB Peers Comparison
Overall Rating
SE:CANTA70Outperform
SE:HNSA55Neutral
SE:ELIC48Neutral
SE:BINV47Neutral- SE:XBRANE42.92Neutral
SE:ATORX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:CANTA | 70Outperform | SEK 451.68M | 2.53 | 63.09% | ― | ― | ― |
| SE:HNSA | 55Neutral | SEK 4.00B | -4.81 | ― | ― | -3.57% | 8.84% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:ELIC | 48Neutral | SEK 177.19M | -7.55 | -56.09% | ― | ― | 14.10% |
| SE:BINV | 47Neutral | SEK 357.32M | -0.58 | -128.54% | ― | -83.67% | -50.29% |
| SE:XBRANE | 43Neutral | SEK 291.57M | -7.19 | -11.52% | ― | -38.80% | -120.18% |
| SE:ATORX | 37Underperform | SEK 35.32M | -0.02 | -439.98% | ― | -99.33% | 64.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:XBRANE | Xbrane Biopharma AB | 13.00 | 2.45 | 23.22% | |
| SE:HNSA | Hansa Biopharma | 37.84 | 7.44 | 24.47% | |
| SE:ATORX | Alligator Bioscience AB | 0.01 | -0.36 | -96.77% | |
| SE:BINV | BioInvent International AB | 4.30 | -28.85 | -87.03% | |
| SE:ELIC | Elicera Therapeutics AB | 2.67 | -3.27 | -55.07% | |
| SE:CANTA | Cantargia AB | 1.72 | -1.56 | -47.56% |
Xbrane Biopharma AB Corporate Events
Xbrane Builds Biosimilars Momentum with FDA Nod and Growing European Sales
Xbrane reported third-quarter 2026 revenue of SEK 54.8 million, driven almost entirely by European sales of Ximluci, and an EBITDA loss of SEK 6.6 million, reflecting continued investment in R&D that accounted for 43 percent of operating costs. C...
Xbrane Wins FDA Nod for Lucamzi Biosimilar to Lucentis
The U.S. Food and Drug Administration has approved Lucamzi, Xbrane Biopharma’s ranibizumab biosimilar to Lucentis, clearing the way for a U.S. launch in 2027 in partnership with commercialization allies. The decision follows extensive analytica...
Xbrane Biopharma to Present Q3 2026 Interim Results Amid Biosimilar Expansion
Xbrane Biopharma AB, a Stockholm-based biotech focused on cost-efficient biosimilar drugs, is building a portfolio of candidates that target reference products with an estimated EUR 23 billion in annual peak sales. Its lead product Ximluci, a biosimi...
Xbrane Reaches Key Milestone as Xdivane Pivotal Trial Fully Enrolls Melanoma Patients
Xbrane Biopharma AB and its strategic partner Intas Pharmaceuticals have completed patient recruitment for the pivotal clinical trial of Xdivane™, a biosimilar candidate to Bristol Myers Squibb’s blockbuster oncology drug Opdivo® (ni...
Xbrane Biopharma Sets Nomination Committee Ahead of 2027 AGM
Xbrane Biopharma AB, a Swedish biotech specializing in cost-efficient biosimilar development, is building a portfolio of biological drugs targeting multi-billion-euro reference markets, with its lead product Ximluci® already authorized and launc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026